Combined antimonial allopurinol therapy in mucosal leishmaniasis

Sampaio, Raimunda Nonata Ribeiro; Marchán, Edgar; Vexenat, A.; Tristão, R. J.; Marsden, Philip D.

doi:10.1590/s0074-02761990000300017

Cited by 7 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…64,65 Since 1982, in vitro studies have demonstrated the possible benefits of allopurinol as a therapeutic option for leishmaniasis. 66 Marsden et al 67 and Sampaio et al 68 reported cases of the use of this drug. Allopurinol, a xanthine oxidase inhibitor, has been demonstrated to be an effective treatment for CL in Asia.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of New World cutaneous leishmaniasis – a systematic review with a meta‐analysis

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Since 1982, in vitro studies have demonstrated the possible benefits of allopurinol as a therapeutic option for leishmaniasis 66 . Marsden et al 67 . and Sampaio et al 68 .…”

Section: Discussionmentioning

confidence: 99%

Treatment of New World cutaneous leishmaniasis – a systematic review with a meta‐analysis

et al. 2008

View full text Add to dashboard Cite

show abstract

“…A randomized clinical trial comparing 28 days vs. 40 days of treatment for MCL was tried as treatment of six patients with mucosal leishmaniasis in an uncontrolled study in Brazil, but only two of the patients failed to show a benefit of prolonged therapy (63% cure rate among each group) [25]. were cured after 45-68 days of therapy [16].…”

Section: Adverse Eventsmentioning

confidence: 99%

Efficacy of Sodium Stibogluconate Alone and in Combination with Allopurinol for Treatment of Mucocutaneous Leishmaniasis

et al. 1997

View full text Add to dashboard Cite

A randomized, open, controlled clinical trial was designed to evaluate the efficacy, tolerance, and safety of sodium stibogluconate plus allopurinol and sodium stibogluconate alone as treatment of patients with mucocutaneous leishmaniasis. In phase 1 of the study, all 22 patients with severe disease had improvement of their lesions, but only two had clinical cure (both of these patients received sodium stibogluconate alone). In phase 2, which included 59 patients with moderate disease, the cure rate among sodium stibogluconate recipients was 75% (21 of 28) compared with 63.6% (14 of 22) among the sodium stibogluconate plus allopurinol recipients. The rates of clinical adverse events were similar among both groups. Thrombocytopenia was more frequent in the sodium stibogluconate plus allopurinol recipients, but the difference was not statistically significant. Eight patients (two sodium stibogluconate recipients and six sodium stibogluconate plus allopurinol recipients) withdrew from the study because of severe thrombocytopenia. In this study, the addition of allopurinol to sodium stibogluconate provided no clinical benefit as treatment of mucocutaneous leishmaniasis.

show abstract